HeartSciences Inc.
HeartSciences Inc. is a U.S.-based medical technology company developing AI-enabled electrocardiography tools that aim to make a standard ECG more clinically useful. Its core products are the cloud-based MyoVista Insights platform and the MyoVista wavECG device, both designed to detect a broader range of cardiac conditions, but neither has yet received FDA marketing clearance.
Tilikausi 2026 · muutos edellisvuodesta
Kehitys 2022–2026
Liiketoiminta
Osuus liikevaihdostaMyoVista Insights provides ECG upload, centralized storage, review, and AI algorithm delivery in clinical workflows.
Proprietary and licensed algorithms intended to detect cardiac dysfunction and other heart disease conditions.
A proprietary resting 12-lead ECG device designed to combine conventional ECG output with AI-derived diagnostic information.
Proprietary electrodes and related components used with the wavECG device on a per-test basis.
Hosting and commercialization of third-party AI-ECG algorithms on the MyoVista Insights platform.
Asiakkaat
HeartSciences sells into healthcare providers and payors that want better cardiac screening, workflow efficiency, and earlier detection of undiagnosed heart disease. The company specifically targets cardiologists, referring physicians, hospitals, primary care settings, and insurance-related populations such as Medicare Advantage plans. Early customers are also used as clinical workflow adopters while regulatory clearance is pending.
Buy the cloud platform and, later, the wavECG device to improve ECG workflow, storage, and diagnostic reach.
Use the platform and device outputs to support diagnosis and referral decisions for cardiac disease.
Adopt the device or cloud workflow for front-line screening where faster triage can improve referral quality.
Potential buyers or influencers because better detection of heart disease can support risk adjustment and care management.
Pilot the MyoVista Insights platform to validate workflow fit and prepare for future algorithm deployment.
Strategia
The company is building a device-agnostic AI-ECG platform first, then layering in its own MyoVista wavECG hardware and proprietary consumables. It is also pursuing third-party algorithm hosting and licensing partnerships, such as the Mount Sinai collaboration, to expand clinical use cases and reduce internal R&D burden. Near term, the key strategic objective is regulatory clearance and workflow adoption; longer term, the goal is recurring revenue from algorithm usage, subscriptions, and consumables.
Commercial sales in the U.S. depend on clearance for the device and future algorithms.
The platform must fit into existing workflows to gain physician and facility acceptance.
Hosting external algorithms can increase clinical value and reduce internal development cost.
Subscriptions, algorithm usage, and consumables can create more durable revenue than one-time device sales.
Maantiede
HeartSciences is headquartered in the United States, but its commercialization strategy is global and explicitly designed to work in any care setting worldwide. Current revenue has been limited and was mainly generated outside the United States through distributor relationships during product development, while future U.S. sales depend on FDA clearance and reimbursement.
Riskit
HeartSciences is still pre-commercial in its core products, so regulatory clearance, reimbursement, and physician acceptance are the main gating factors for future revenue. The company also faces financing risk, going-concern pressure, supplier dependence, and execution risk as it tries to move from development-stage revenue to a scalable clinical product business.
- Regulatory clearance delay or failureVaikutus: KriittinenTodennäköisyys: Korkea
The company cannot market the wavECG in the U.S. without FDA clearance, and future algorithms also require regulatory pathways.
Kohdistuu: MyoVista wavECG and future AI-ECG algorithms
- Insufficient funding and going-concern pressureVaikutus: KriittinenTodennäköisyys: Korkea
The company has limited cash, recurring losses, and expects to rely on equity financing to continue operations.
Kohdistuu - Reimbursement and coverage uncertaintyVaikutus: KorkeaTodennäköisyys: Korkea
Hospitals and payors may not adopt products without coverage, especially for AI-ECG use cases.
Kohdistuu: U.S. and international commercialization
- Physician and customer acceptanceVaikutus: KorkeaTodennäköisyys: Korkea
Adoption depends on clinicians believing the products are useful, reliable, and easy to integrate.
Kohdistuu - Nasdaq listing compliance and dilutionVaikutus: KeskitasoTodennäköisyys: Korkea
Ongoing losses and equity financing can pressure listing status and dilute shareholders.
Kohdistuu: Capital markets access
- Supplier and manufacturing dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The device relies on third-party components and assembly, creating quality, cost, and delivery risk.
Kohdistuu: MyoVista wavECG hardware and consumables
Kirjanpito
Harkinnanvaraiset erätDifferent deliverables may be recognized at different points in time or over time as commercialization evolves.
Vaikutus: Could materially affect reported revenue timing and gross margin
The company uses equity awards and must estimate fair value and vesting expense.
Vaikutus: Affects operating expenses and net loss
Limited cash and recurring losses require explicit assessment of funding sufficiency.
Vaikutus: Important for solvency assessment and capital-raising expectations
Preferred stock, warrants, notes, and equity-linked financings can require valuation judgments.
Vaikutus: Can create volatility in other income/expense and equity balances
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
HeartBeam, Inc.
BEAT · Surgical & Medical Instruments & Apparatus
Heartflow, Inc.
HTFL · Surgical & Medical Instruments & Apparatus
iRhythm Holdings, Inc.
IRTC · Surgical & Medical Instruments & Apparatus
Cardio Diagnostics Holdings, Inc.
CDIOW · In Vitro & In Vivo Diagnostic Substances
Pulse Biosciences, Inc
PLSE · Surgical & Medical Instruments & Apparatus
Pulse Biosciences is a U.S.-based medical technology company focused on developing and commercializing nonthermal pulsed field ablation systems.
Odyssey Health, Inc.
ODYY · Surgical & Medical Instruments & Apparatus
Päivitetty: 24.9.2026